Adeno-associated virus 2 (AAV2) vectors transduce fibroblasts and mesenchymal stem cells (MSCs) inefficiently, which limits their potential widespread applicability in combinatorial gene and cell therapy. We have reported that AAV2 vectors fail to traffic efficiently to the nucleus in murine fibroblasts. We have also reported that site-directed mutagenesis of surface-exposed tyrosine residues on viral capsids leads to improved intracellular trafficking of the mutant vectors, and the transduction efficiency of the single tyrosine-mutant vectors is *10-fold higher in human cells. In the current studies, we evaluated the transduction efficiency of single as well as multiple tyrosine-mutant AAV2 vectors in murine fibroblasts. Our results indicate that the Y444F mutant vectors transduce these cells most efficiently among the seven single-mutant vectors, with >30-fold increase in transgene expression compared with the wild-type vectors. When the Y444F mutation is combined with additional mutations (Y500F and Y730F), the transduction efficiency of the triple-mutant vectors is increased by *130-fold and the viral intracellular trafficking is also significant improved. Similarly, the triple-mutant vectors are capable of transducing up to 80-90% of bone marrow-derived primary murine as well as human MSCs. Thus, high-efficiency transduction of fibroblasts with reprogramming genes to generate induced pluripotent stem cells, and the MSCs for delivering therapeutic genes, should now be feasible with the tyrosine-mutant AAV vectors.
Introduction
M esenchymal stem cells (MSCs) and fibroblasts are attractive targets for gene and cell therapies of inherited and acquired disorders. MSCs are multipotent, nonhematopoietic stem cells capable of self-renewal and can be used as a means of delivering genes to repair or regenerate damaged or diseased tissues and organs (Reiser et al., 2005) .
Thus, the use of viral vectors for MSC gene transfer has gained prominence, with retroviral and lentiviral vectors being the most rigorously pursued (Chuah et al., 2000; Zhang et al., 2002; Shakhbazau et al., 2008; Barzilay et al., 2009; Uchibori et al., 2009) . Second, mouse fibroblasts have been used to develop induced pluripotent stem (iPS) cells by Yamanaka and colleagues (Takahashi and Yamanaka, 2006) . In subsequent studies, both mouse and human fibroblasts have been reprogrammed in vitro into iPS cells through viral or nonviral transduction of combinations of several transcription factors, including Oct4, Sox2, Myc, Klf4, Nanog, Lin28, H-TERT, and SV40 L-T (Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007; Park et al., 2008) . More recently, successful gene replacement in the iPS cells derived from autologous skin was reported and the corrected iPS cells were differentiated into hematopoietic progenitors, which led to correction of sickle cell anemia in a murine model in vivo (Hanna et al., 2007) . These studies indicate that an effective patient-specific cell therapy using autologous MSCs or fibroblasts can be developed in the near future. However, it is of note that retroviruses and lentivirus are either the etiologic agents of, or are intimately associated with, malignant disorders (Weiss et al., 1984) . Recombinant retro-and lentiviral vectors can also undergo random integration into host chromosome, thereby elevating the risk of insertional mutagenesis (Cockrell and Kafri, 2007; Nair, 2008) . Thus, development of alternative vector systems, such as adeno-associated virus (AAV), needs to be pursued, given the proven safety of AAV vectors in several Phase I/II clinical trials (Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008) .
The adeno-associated virus 2 (AAV2) is a small, singlestranded DNA-containing nonpathogenic human parvovirus with the ability to transduce a wide variety of cells and tissues both in vitro and in vivo (Muzyczka, 1992; Flotte et al., 1993; Xiao et al., 1996; Snyder et al., 1997) . However, a number of nonpermissive cell types have also been identified (Ponnazhagan et al., 1996; Bartlett et al., 1999; Girod et al., 1999) . Even in cells that allow infection, the level of infection or transgene expression is variable due to well-documented impediments in virus-host cell interactions during the life cycle of AAV2 (Qing et al., 1999 (Qing et al., , 2001 Hansen et al., 2000 Hansen et al., , 2001a Zhong et al., 2006) . In murine fibroblasts, the ratelimiting step for AAV-mediated transgene expression appears to be the intracellular trafficking and capsid uncoating steps, as we have demonstrated earlier (Hansen et al., 2000) . And, in MSCs, the efficiency of AAV2 vector-mediated transduction has so far been not optimal ( Ju et al., 2004; Kumar et al., 2004; McMahon et al., 2006; Stender et al., 2007) . Thus, it is critical to develop novel AAV vectors that can target and transduce both of these cell types at highefficiency, for their widespread applicability in combinatorial gene and cell transfer applications.
Our recent studies have yielded insights into key steps in the intracellular trafficking of AAV and led the development of novel AAV vectors that are capable of high-efficiency transduction at lower doses (Zhong et al., 2007 (Zhong et al., , 2008a ). Then we found that mutations of critical surface-exposed tyrosine residues on AAV2 capsids circumvent the ubiquitination step, thereby avoiding proteasome-mediated degradation and resulting in high-efficiency transduction by these vectors in human cells in vitro and murine hepatocytes in vivo (Zhong et al., 2008b) . As described by Markusic et al. (2010) , we generated multiple combinations of tyrosine mutants of AAV2 capsids, including a triple-mutant (Y730Fþ Y500Fþ Y444F), consisting of the three best performing single tyrosine-mutants, and evaluated whether the transduction efficiency could be augmented further. Of all the combinations tested, the triple-mutant vector had the highest level of gene transfer, *4-fold more efficient than the single mutants. Both the Y730F and triple-mutant vectors provided long-term therapeutic expression of human factor IX in a hemophilia B mouse model. Based on these data, the current studies were designed to first test if the introduction of tyrosine mutations into the AAV2 viral capsid could significantly improve murine fibroblast and MSC gene transfer and also deduce the underlying mechanism of enhanced transduction, if any, by the tyrosinemutant vectors in these therapeutically important cell types.
Materials and Methods

Recombinant AAV2 vectors, plasmids, antibodies, and chemicals
Highly purified stocks of self-complementary AAV2 (scAAV2) wild-type (WT) vectors containing the enhanced green fluorescence protein (EGFP) gene driven by the chicken b-actin (CBA) promoter (scAAV2-EGFP-WT) were generated as described previously and quantified by slot-blot hybridization as described (Kube and Srivastava, 1997; Liu et al., 2003) . An AAV2-helper plasmid, pACG-2, containing the AAV2 rep gene with an ACG start codon, was generously provided by Dr. R. Jude Samulski (University of North Carolina at Chapel Hill, Chapel Hill, NC). An scAAV2 cloning vector, pdsCBA-EGFP, was a kind gift from Dr. Xiao Xiao (University of North Carolina at Chapel Hill). All primary antibodies were purchased from BD Biosciences Pharmingen (San Jose, CA), and Dynabeads sheep anti-rat IgG was obtained from Invitrogen (Carlsbad, CA). All chemicals and reagents used in this study were purchased from Sigma-Aldrich Co. (St. Louis, MO).
Construction of surface-exposed tyrosine-mutant AAV2 capsid plasmid A two-stage procedure, based on QuikChange II sitedirected mutagenesis (Stratagene, La Jolla, CA), was performed using plasmid pACG-2 as described previously (Wang and Malcolm, 1999) . In brief, in stage one, two PCR extension reactions were performed in separate tubes for each mutant. One tube contained the forward PCR primer and the other contained the reverse primer (Zhong et al., 2008b) . In stage two, the two reactions were mixed and a standard PCR mutagenesis assay was carried out as per the manufacturer's instructions. PCR primers were designed to introduce changes from tyrosine to phenylalanine residues, as well as a silent change to create a new restriction endonuclease site for screening purposes (Zhong et al., 2008b) . All multiple mutant AAV2 capsid plasmids were constructed using standard subcloning strategies. All mutants were screened with the appropriate restriction enzyme and were sequenced prior to use.
Cells
Murine fibroblasts. The murine fibroblast cell line NIH 3T3 was obtained from the American Type Culture Collection (Manassas, VA). Murine embryo fibroblast (MEF)
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cultures were generated from the WT (WT-MEF) or FKBP52-knockout (FKBP52-KO MEF) mice as described previously . Cells were cultured and maintained in DMEM/F12 media (GIBCO, Carlsbad, CA) containing 10% fetal bovine serum (FBS) and 1% (v/v) concentrations of penicillin and streptomycin and supplemented with 2 mM L-glutamine.
MSC isolation and purification. Murine bone marrowderived MSCs were isolated from C57BL/6 mice by negative selection as described previously (Baddoo et al., 2003) . In brief, bone marrow obtained from the long bones of 4-weekold C57BL/6 mice were suspended in a-MEM containing L-lutamine, but no ribonucleosides or deoxyribonucleosides (Invitrogen) and supplemented with 10% FBS (SigmaAldrich), 100 U/ml penicillin, and 100 U/ml streptomycin. Whole bone marrow cells were cultured in the same medium in 100-mm culture dishes (1.45Â10 6 cells/cm 2 ) at 378C with 5% CO 2 for 72 hr, and nonadherent cells were removed by aspiration. Cells were cultured for an additional 5-7 days with a single medium change and harvested by gentle scraping after incubation in 0.25% trypsin with 1 mM EDTA for 5 min. To remove cell clumps, the cell pellet was dispersed by gentle agitation, resuspended in 20 ml of Hanks' balanced salt solution (HBBS), and filtered through a 70-mm filter (Falcon, Franklin Lakes, NJ). Cells were resuspended in HBSS at a maximum density of 4Â10 7 cells/ml and incubated on a rotator for 1 hr at 48C prior to immunodepletion. For immunodepletion, anti-CD11b, anti-CD34, and anti-CD45 antibodies (rat anti-mouse IgG) (1 mg/10 6 cells) (BD Biosciences Pharmingen) were added and cells were incubated on a rotator for 40 min at 48C. Cells were spun down at 48C and supernatant was removed. The cells pellets were resuspended in 0.2 ml of washed anti-rat IgG-conjugated Dynabeads and 1 ml of HBSS with 10% FBS, and incubated on a rotator for 20 min at 48C. CD11b-, CD34-, and CD45-positive cells were separated from negative cells by Dynabeads sheep anti-rat IgG (Invitrogen). The immunodepleted cells were plated at approximately 1Â10 6 cells per T75 flask and cultured in complete medium at 378C with 5% CO 2 in a humidified chamber with medium changes two or three times weekly. The expression profiles of surface antigens on the immunodepleted MSCs were evaluated by flow cytometry using rat anti-mouse antibodies (BD Biosciences Pharmingen) against CD9, CD29 and CD81, which are uniformly expressed in murine MSCs.
Human MSCs were purchased from ScienCell Research Laboratories (Carlsbad, CA) and maintained in the complete MSC culture medium obtained from ScienCell Research Laboratories.
Recombinant AAV2 vector transduction assays in vitro
Approximately 1Â10 5 murine NIH 3T3, WT-MEF, or FKBP52-KO MEF cells were plated in 12-well plates and incubated at 378C for 12 hr. Cells were washed once with DMEM/F12 media and then infected at 378C for 2 hr either with phosphate-buffered saline (PBS, mock) or with the WT or the single or multiple tyrosine-mutant scAAV2-EGFP vectors at a multiplicity of infection (MOI) of 500, 1,000, or 2,000 vgs/cell in various experiments. To compare the efficiency of the WT and triple-mutant vectors, in the uncoating process and transgene expression under DNA replication stress, VP16 (etoposide, Sigma-Aldrich) was added at a final concentration of 10 mM to murine WT-MEF cells or FKBP52-KO MEF cells. Forty-eight hours after infection, transgene expression was detected by fluorescence microscopy using an Axiovert 25 fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY). Images from five visual fields were analyzed quantitatively by ImageJ analysis software (National Institutes of Health, Bethesda, MD). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean AE SD).
Approximately 1Â10 5 murine or human MSCs (within five passages) were used for transductions with recombinant AAV2 vectors in 12-well plates as described previously (Zhong et al., 2004 (Zhong et al., , 2007 . Transgene expression was evaluated 5 days after transduction by EGFP imaging using fluorescence microscopy. Analysis of variance (ANOVA) was used to compare test results with the control, and they were determined to be statistically significant.
Isolation of nuclear and cytoplasmic fractions from MEFs and Southern blot analysis for AAV2 intracellular trafficking
Nuclear and cytoplasmic fractions from murine WT-MEF cells or FKBP52-KO MEF cells were isolated as described previously (Hansen et al., 2000; Zhong et al., 2004) . In brief, mock-infected or the WT or the triple-mutant scAAV2-EGFP vector-infected cells were washed twice with PBS at 18 hr postinfection, treated with 0.01% trypsin, and washed extensively with PBS to remove any adsorbed and unadsorbed virus particles. Cell pellets were gently resuspended in 200 ml of hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride) and incubated on ice for 5 min, after which 10 ml of 10% NP-40 was added, and observed under a light microscope. Samples were mixed gently and centrifuged for 5 min at 500 rpm at 48C. Supernatants (cytoplasmic fractions) were decanted and stored on ice. Pellets (nuclear fractions) were washed twice with 1 ml of hypotonic buffer and stored on ice. The purity of each fraction was determined to be >95%, as measured by the absence of acid phosphatase activity (nuclear fractions) and absence of histone H3 (cytoplasmic fractions) as described previously (Hansen et al., 2000; Zhong et al., 2004) . Low-M r DNA samples from nuclear and cytoplasmic fractions were isolated and electrophoresed on 1% agarose gels followed by Southern blot hybridization using a 32 P-labeled EGFP-specific DNA probe as described previously (Zhong et al., 2004) . Densitometric scanning of autoradiographs for the quantitation was performed using ImageJ analysis software.
Separation of intact AAV2 virions from MEFs and Southern blot analysis to determine rate of AAV capsid uncoating
Equivalent numbers (*2Â10 6 ) of WT-MEF cells or FKBP52-KO MEF cells were infected with the WT or the triple-mutant scAAV2-EGFP vectors at 1Â10 6 vgs/cell at 378C for 2 hr. The nuclear and cytoplasmic fractions were isolated 18 or 48 hr postinfection as described above. The supernatants (cytoplasmic fraction) were decanted. After washing twice with 1 ml of hypotonic buffer, the pellets (nuclear fraction) were resuspended in 400 ml of PBS containing 2 mM MgCl 2 . Nuclear fractions (200 ml each) were either mock-treated, or digested with Benzonase nuclease (Novagen Inc., Madison, MI) (100 U/ml) at 378C for 1 hr. EDTA was added to a final concentration of 100 mM, followed by heat inactivation of Benzonase nuclease at 758C for 15 min. Low-M r DNA was isolated by the method described previously (Hansen et al., 2000 (Hansen et al., , 2001a Zhong et al., 2004) , and AAV genomes were electrophoresed on 1% agarose gels and analyzed by Southern blot hybridization using a 32 Plabeled EGFP-specific DNA probe as described above. Densitometric scanning of autoradiographs, for the quantitation of relative amounts of viral genomes, was evaluated with ImageJ analysis software (National Institutes of Health).
Results
Single mutations in surface-exposed tyrosine residues improve the transduction efficiency of AAV2 vectors in murine NIH 3T3 cells
To develop the optimal AAV vectors for fibroblast and MSC gene transfer, we first tested the transduction efficiency of each of the seven (Y252F, Y272F, Y444F, Y500F, Y700F, Y704F, and Y730F) surface-exposed tyrosine-mutant scAAV2-EGFP vectors in comparison with that of the WT vectors in murine NIH 3T3 cells in vitro under identical conditions. From the results shown in Fig. 1 , it is evident that whereas mock-infected NIH 3T3 cells showed no green fluorescence, the transduction efficiency of each of the tyrosinemutant vectors, 48 hr postinfection, was significantly higher compared with that of the WT scAAV2-EGFP vector at 2,000 viral particles per cell. Specifically, the transduction efficiency of Y444F vectors was maximal, *193-fold higher than that of the WT vector (Fig. 1B) . Similarly, the Y730F and the Y500F mutants also had significant enhancement in EGFP expression (*57-and 44-fold, respectively). It is interesting to note that the tyrosine-mutant efficacy data from NIH 3T3 cells are different from our previously published data with HeLa cells (Zhong et al., 2008b) , where the Y730F mutant was the most efficacious (*11-fold higher transduction efficiency vs. the WT vector) (Fig. 2) . These data suggest that tyrosine mutants have different levels of efficacy in different cell/tissue types, possibly due to the differences in the intracellular milieus in different species and/or conformation-dependent binding and accessibility to host cellular factors.
Multiple mutations in the surface-exposed tyrosine residues of AAV2 vectors further improve the transduction efficiency in primary WT murine fibroblasts but not in FKBP52-KO murine fibroblasts
To examine whether various combinations of the three best performing single tyrosine mutants (Y444F > Y730F > Y500F) could lead to further enhancement in the transduction efficiency, we first compared the efficacy of these single mutants with double (Y444þ730F) and triple (Y444þ500þ 730F) tyrosine-mutant vectors in WT-MEFs. As expected, the transduction efficiency of each of the single and multiple tyrosine-mutant vectors was significantly higher compared with that of the WT scAAV2-EGFP vector at an MOI of 1,000 vgs/cell, 48 hr postinfection ( Fig. 3A and B) . Interestingly, the triple-mutant (Y444þ500þ730F) led to an additional *4-fold increase in transgene expression, followed by a *1.5-fold increase with the Y444þ730F double-mutant, compared with the single-mutant vectors. The efficacy of the triple-mutant vector in WT-MEFs is in agreement with our recent studies, where we have documented that the triplemutant vector had the highest level of gene transfer, *3-5-fold more efficient than the single mutants in the HeLa cells in vitro and in murine hepatocytes in vivo (Markusic et al., 2010) . The transduction efficiency of the triple-mutant vector was *130-fold higher than that of the WT AAV vector. These vectors were also tested in NIH 3T3 and 20,000 and WT-MEFs at an MOI of 5,000 and 10,000 for 2 days or 5 days (Figs. 3C-E and 4). As can be seen, whereas WT AAV2 vectors transduced either NIH 3T3 or WT-MEF cells very poorly, even at high MOIs, the triple-mutant AAV2 led to high efficiency transduction under identical conditions (*50-350-fold increase).
As we have previously shown that the tyrosine-mutant vectors can traffic efficiently into the nucleus bypassing the cellular proteasome-mediated degradation (Zhong et al., 2008a,b) and that a host-cell chaperone protein, FKBP52, is required for intracellular trafficking of WT AAV , we wished to examine if FKBP52 could mediate enhanced transduction of the tyrosine-mutant vectors. To test this hypothesis, we compared the transduction efficacy of the WT and triple-mutant scAAV vectors in FKBP52-KO MEFs. As can be seen in Fig. 3A , little or no transgene expression was seen in FKBP52-KO MEFs infected with either the WT or the triple-mutant vectors, compared with the WT-MEFs (Fig.  3A) . These data suggest that FKBP52, being a cellular chaperone protein, plays an important role in the intracellular trafficking and/or uncoating process of the triple-mutant vectors as we have described previously for the WT vectors .
FKBP52 is required for intracellular trafficking of the WT but not for the triple-mutant AAV2 vectors
As we only detected very low transgene expression in FKBP52-KO MEFs infected with either the WT or the triplemutant vectors, we next examined the fate of the input viral DNA in these cells in comparison with the WT-MEFs. Low-M r DNA samples from nuclear or cytoplasmic fractions of mock-or vector-transduced cells were isolated 18 hr posttransduction and analyzed on Southern blots. As can be seen in Fig. 5A (lane 5) , and the densitometric scanning in Fig. 5B , *45% of the input AAV2 DNA was present in the nuclear fraction in the WT-MEF cells infected with the WT vector, consistent with our previously published studies (Zhong et al., 2007) . Interestingly, the amount of the input triplemutant AAV2 vector DNA in the nuclear fraction was increased to *65% (Fig. 5A, lane 6, and B) . These results further confirm that, as with single-mutant tyrosine vectors (Zhong et al., 2008b) , multiple mutations in the surfaceexposed tyrosine residues also facilitate enhanced nuclear transport of AAV2 vectors. However, in FKBP52-KO MEFs, in which *30% input DNA of the WT vectors was detected in the nuclear fraction (Fig. 5A, lane 11, and B) , nearly 75% of the input DNA was seen in the nuclear fraction from cells transduced with the triple-mutant vectors. These data suggest a diminished role for FKBP52 in the intracellular trafficking of the triple-mutant vectors compared with the WT
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TRANSDUCTION EFFICIENCY OF TYROSINE-MUTANT AAV2 VECTORS
vectors, possibly due to the absence of the tyrosine residues at positions 730, 500, and 444 that may provide binding sites for the dephosphorylated forms of FKBP52 in the cytosol, and then traffic the vectors into the nucleus (Zhong et al., 2007) . The absence of these critical residues on AAV capsids in tyrosine-mutant vectors may prevent binding with FKBP52, and thus promote nuclear translocation by avoiding the ubiquitin/proteasomal pathway, because other tetracopeptide-containing immunophilins such as FKBP38 are known to anchor with proteasomes in the cytosol (Nakagawa et al., 2007).
FKBP52 is involved in the uncoating of AAV2 vectors
To investigate the extent of AAV vector uncoating in the WT-MEFs and FKBP52-KO MEFs, cells were infected with the WT or the triple-mutant scAAV vectors, and nuclear fractions were isolated 18 and 48 hr postinfection. Samples 
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were either mock-treated or treated with Benzonase nuclease, which would be expected to digest the virus DNA after uncoating of the capsid structure. It is important to note that others and we have shown that DNA in the intact nuclei can be completely digested with the DNase protocol used here . Low-M r DNA isolated from equivalent numbers of cells was then analyzed on Southern blots. These results are shown in Fig. 6 . As can be seen in Fig. 6A and its quantitative analysis in Fig. 6C , 18 hr posttransduction in WT-MEFs, the triple-mutant vector had a better uncoating profile due to its enhanced trafficking ability, as only *45% of DNA for the triple-mutant vector remained resistant to Benzonase nuclease digestion compared with *80% of the input DNA of the WT AAV vector. A similar trend of uncoating extended up to 48 hr in WT-MEFs for both vectors. However, in the absence of FKBP52, as in FKBP52-KO MEFs (Fig. 6B) , almost equal amounts (*100%) of input WT and triple-mutant vectors remained intact. These data strongly suggest that FKBP52 is required for the capsid uncoating of both the WT and the triple-mutant vectors. The rapid uncoating of the triple-mutant vectors at 48 hr in WT-MEFs (*48% to 2%), but not in FKBP52-KO MEFs (100% to 90%), or 18 hr postinfection, also suggests that nucleus-localized FKBP52 can facilitate uncoating of the triple-mutant vectors in the absence of cytoplasmic FKBP52 bound to AAV capsids, as is the case with the WT vectors. In this context, it is interesting to note that *80% of cellular FKBP52 is localized to the nucleus (Czar et al., 1994a,b) .
A direct correlation exists between the rate of capsid uncoating and the extent of transgene expression Treatment with topoisomerase inhibitors, such as etoposide (VP16), has previously been shown to improve transgene expression from AAV vectors (Koeberl et al., 1997) . To examine whether enhanced transgene expression could be achieved from the fraction of uncoated DNA in both WT and FKBP52-KO MEFs, cells were treated with VP16 following infections with the WT and the triple-mutant scAAV vectors. As can be seen in Fig. 7 , a significantly higher level of transgene expression was observed in WT-MEFs treated with VP16 for both the WT and the triple-mutant AAV vectors compared with that in the FKBP52-KO MEF cells. This increase in transgene expression corroborated well with the levels of vector genomes released following FKBP52-mediated uncoating of AAV capsids to serve as templates for VP16 activity.
Tyrosine mutations improve the transduction efficiency of AAV2 vectors in primary murine MSCs
To establish the feasibility of the use of tyrosine-mutant vectors for MSC gene transfer, the transduction efficiency of each of the seven surface-exposed tyrosine-mutant scAAV2-EGFP vectors (Y252F, Y272F, Y444F, Y500F, Y700F, Y704F, and Y730F) was analyzed in murine MSCs. Primary murine bone marrow-derived MSCs were isolated from C57BL/6 mice as described previously (Baddoo et al., 2003) . Transgene expression was detected by fluorescence microscopy 5 days postinfection. As shown in Fig. 8A , the transduction efficiency of the Y500F and Y730F vectors was *3-10-fold higher than that of the WT vector, consistent with our previous studies (Zhong et al., 2008b) , as well as those described by Markusic et al. (2010) . The transduction efficiency of the Y444F vectors was *13-fold higher than that of the WT vectors (Fig. 8A) . In addition, the following combinations of the mutants were also evaluated in murine MSCs at 2,000 vgs/cell: three double: Y444þ500F, Y444þ730F, Y500þ730F; one triple: Y444þ500þ730F; and one septuple: Y252þ272þ 444þ500þ700þ704þ730F. The combination of mutant Y444F with other mutants, such as two double-mutants (Y444þ500F and Y444þ730F), the triple-mutant (Y444þ500þ730F), and the septuple-mutant, led to *21-31-fold and *45-fold increases in EGFP transgene expression in murine MSCs compared with the WT vectors (Fig. 8B) . These data indicate that the triple-mutant is the optimal tyrosine-mutant AAV2 vector for efficient transduction of primary murine MSCs. The enhanced transduction efficiency of the triplemutant vector offers a potentially useful approach for generating iPS cells.
Tyrosine mutations also improve the transduction efficiency of AAV2 vectors in primary human MSCs
We next examined whether single or multiple tyrosine mutations could also improve the transduction efficiency of AAV2 vectors in primary human MSCs. The efficacy of WT as well as single and multiple tyrosine-mutant vectors was evaluated in primary human bone marrow-derived MSCs in vitro. The efficiency of single tyrosine-mutant vectors was significantly higher, and ranged between 5-and 6-fold, compared with that of the WT vector (Fig. 9) at 5,000 vgs/ cell. The multiple-mutant vectors led to a further increase in EGFP expression (Fig. 9A) , in which two double mutants (Y444þ500F and Y444þ730F) led to *7-8-fold increase. The triple-mutant (Y444þ500þ730F) vectors led to *11-fold increase, and the septuple-mutant resulted in *9-fold increase in EGFP transgene expression compared with the WT vectors (Fig. 9B) . As determined by fluorescence microscopy, *80-90% of these cells were transduced by the triple-mutant vectors 5 days posttransduction. This enhanced transduction potential of human MSCs mediated by the triple-mutant vector offers a potentially promising platform for therapeutic applications.
FIG. 6. Southern blot analyses for uncoating of WT and the triple-mutant AAV vectors in normal (A) and FKBP52-KO (B)
MEFs. Equivalent amounts of nuclear samples isolated from mock-transduced or vector-transduced cells at 18 hr or 48 hr were either not treated, or treated exhaustively with Benzonase nuclease. Low M r DNA isolated from these samples was analyzed on Southern blots using a 32 P-labeled EGFP-specific DNA probe as described above. (C) Densitometric quantitation of the data in A and B. Color images available online at www.liebertonline.com/hum. 
Discussion
Correction of genetic defects is one of the most elegant and fundamental approaches to the treatment of human diseases, including cancer, AIDS, metabolic and inherited diseases (Anderson, 1998) . However, despite continuous improvement in vector technology, efficient and specific delivery of a therapeutic gene to the target cells still remains a major block in clinical gene transfer studies. Alternatively, stem cells, including the hematopoietic stem cells (HSCs), MSCs, and more recently iPS cells, are considered attractive targets for ex vivo modification with gene therapy vectors for the potential cellular and gene therapy of inherited and acquired disorders (Takahashi and Yamanaka, 2006; Zhong et al., 2006; Stender et al., 2007) . These cells possess the properties of self-renewal, are capable of differentiating into multiple lineages, have the ability to home to sites of injury, and, most importantly, are hypoimmunogenic when ex vivo transduced, making allogeneic transplantation of these cells a possibility. Of these, the use of MSCs and iPS cells is considered widely feasible over that of HSCs due to their ease of isolation and a high capacity for in vitro expansion and further genetic modifications with viral vectors.
Remarkable progress has been made in the recent past in using retroviral or lentiviral vectors to deliver therapeutic genes into MSCs (Zhang et al., 2002; Lee et al., 2004; Reiser et al., 2005; Barzilay et al., 2009; Jacome et al., 2009) or in deriving iPS cells from adult somatic cells (Welstead et al., 2008; Sommer et al., 2009) Townes, 2008) . However, both retroviral and lentiviral vectors undergo random integration into host chromosomal DNA, and there is persistent risk for insertional mutagenesis (Cockrell and Kafri, 2007; Nair, 2008) . The development of leukemia in four treated children in an X-linked severe combined immunodeficiency clinical trial using retroviral vectors has re-emphasized the risks related to gene therapy (HaceinBey-Abina et al., 2003; Kohn et al., 2003; Nair, 2008) . More recently, nonintegrating adenoviral vectors (Stadtfeld et al., 2008) and plasmid DNAs (Okita et al., 2008) have been used to deliver Klf4, Oct3/4, and Sox2 genes to fibroblasts, but the efficiency of reprogramming is low, ranging between 0.01 and 0.1%. Thus, we believe that further development of alternative vector systems, such as AAV, needs to be pursued for their potential ability to infect MSCs and fibroblasts, as well as to generate iPS cells at high efficiency, given the proven safety of AAV vectors in several clinical trials (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008) .
Despite the impressive safety record of AAV vectors, the efficacy of gene transfer in MSCs and in fibroblasts is suboptimal (Reiser et al., 2005) . A comparative study of viral and nonviral vectors showed that AAV serotypes 1, 2, 4, 5, and 6 were least effective in rat and rabbit MSCs compared with other means of gene transfer (McMahon et al., 2006) . In contrast, a vector dose-dependent enhancement in transduction efficiency of 1-65% has been reported in human MSCs, but those authors concluded that host cellular barriers may contribute to the relatively restricted transgene expression observed in MSCs (Stender et al., 2007) . Importantly, the AAV2 vector-transduced MSCs in this study retained their multipotential activity compared with the untransduced controls (Stender et al., 2007) . Similarly, in fibroblasts, we and others have reported *30-fold lower levels of AAV2 DNA replication when compared with 293 or HeLa cells (Hansen et al., 2000; Bhrigu and Trempe, 2009) . Therefore, it becomes important to elucidate the fundamental steps in the life cycle of AAV and its host cell interactions to overcome barriers leading to a decreased transduction efficiency of AAV in both MSCs and fibroblasts.
We have previously undertaken systematic studies in fibroblasts, including cell-surface receptor-and coreceptormediated viral binding and entry (Hansen et al., 2000) , intracellular trafficking (Hansen et al., 2000 (Hansen et al., , 2001a Zhao et al., 2006) , nuclear transport (Hansen et al., 2001b) , uncoating and viral second-strand DNA synthesis , and identified intracellular trafficking as the major impediment for efficient transgene expression from WT AAV vectors. Subsequently, we documented that, during the process of navigation through the late endosome, EGFR-PTK-induced tyrosine phosphorylation of AAV2 capsid proteins promotes ubiquitination and degradation of AAV2, thus leading to impairment of viral nuclear transport and decrease in transduction efficiency in intact cells (Zhong et al., 2007 (Zhong et al., , 2008a . Based on these studies, we mutated each of the seven surface-exposed tyrosine residues on viral capsids that are phosphorylated by EGFR-PTK, to yield AAV2 vectors with significantly increased transduction efficiency in HeLa cells in vitro as well as in C57BL/6 mice in vivo, compared with their WT counterpart (Zhong et al., 2008b) . In the present study, we have further improved the transgene expression in fibroblasts by >130-fold, using a combination of either single or multiple tyrosine-mutants and demonstrated that the triple-mutant AAV2 is by far the optimal vector to transduce fibroblasts.
As the level of transgene expression from this triplemutant vector was compromised in FKBP52-KO fibroblasts, we further examined the role of FKBP52 in both intracellular trafficking and uncoating of the triple-mutant vector. Our detailed subcellular studies suggest that FKBP52 plays a major role in intracellular trafficking of the WT AAV vector, but not the triple-mutant vector. However, FKBP52 is required for uncoating of both the WT and the triple-mutant AAV vectors. It is possible that FKBP52 binds to different regions of the AAV capsid, depending on whether they are in the cytosol or in the nucleus, and surface-exposed tyrosine residues in the WT vector may provide docking sites for cytosolic FKBP52, but not nuclear FKBP52. This could explain why the triple-mutant vectors can still traffic efficiently into the nucleus in FKBP52-KO cells, by an additive effect of FKBP52's ability to escape from the proteasomal machinery, but it gets trapped in the nucleus of these cells during the uncoating process. Alternatively, it is possible for FKBP52 to have dual roles in intracellular trafficking and capsid uncoating by a molecular switch involving its phosphorylation and dephosphorylation status. Cytoplasmic FKBP52 may bind to phosphorylated-tyrosine residues present in the WT AAV capsid and facilitate its intracellular trafficking, but while inside the nucleus, FKBP52 may become phosphorylated to initiate uncoating. In the absence of AAV capsidbound cytoplasmic FKBP52 within the nucleus, as with the triple-mutant vectors, the phosphorylated forms of nuclear FKBP52 may substitute for uncoating activity. Then, in this proverbial vicious cycle of AAV-host cell protein interactions, phosphorylated FKBP52 blocks the viral second-strand DNA synthesis, as we have described previously Qing et al., 1998) . Further studies are needed to confirm this hypothesis and the trafficking and uncoating advantage or disadvantage, if any, using the septuple tyrosine-mutant vectors.
The availability of a highly efficacious triple-mutant AAV vector that can transduce fibroblasts *130-fold more efficiently, and exhibits transgene expression in *90% of infected cells, can now be exploited to generate iPS cells at a higher frequency. Similarly, the efficacy of AAV2 tyrosinemutant vectors in transducing both murine and human MSCs was also documented. Given that AAV2 remains the predominant serotype vector currently in use in human gene therapy (Flotte et al., 1996 (Flotte et al., , 2004 Kay et al., 2000; Aitken et al., 2001; Wagner et al., 2002; Manno et al., 2003; Snyder and Francis, 2005) , coupled with the fact it is also the best characterized in terms of vector toxicology, we achieved >90% transduction efficiency in MSCs at MOIs of 5,000 of the tyrosine-mutant vectors, levels that will be capable of achieving physiological correction with most therapeutic proteins. This is critical, because the requirement of relatively high vector doses (>10,000-100,000) has been reported to achieve only suboptimal transduction of MSCs with AAV vectors (McMahon et al., 2006; Stender et al., 2007) . The availability of a large repertoire of multiple tyrosine-mutant AAV2 vectors and other AAV serotypes (AAV1-AAV12) (Daya and Berns, 2008) offers hope for achieving 100% transduction at reduced vector doses in the therapeutically important fibroblasts and MSCs.
In summary, this study clearly demonstrates that a thorough understanding of the fundamental steps in AAV-host cell interactions can lead to development of efficacious vectors that can optimally transduce semipermissive cells, which have significant implications in the use of AAV vectors in both gene and cell therapy.
